Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?

This article was originally published in PharmAsia News

Executive Summary

The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence

You may also be interested in...



EFPIA Hopes To Shift Conversation In Japan From Pricing To Funding

The European pharma trade group also plans communication offensive on health technology assessment as Japan reconsiders pricing methodology.

Japan 2012 NHI Price Revision Takes Shape, Long-Listed Products See Smaller Cuts Than Expected

Japan's MHLW and Finance Ministry face off on the steps needed to shave reimbursement costs.

Chuikyo's Pilot For Premium Reimbursement Pricing Under Review: One Of Three Fates By Year-end

Related Content

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel